Short Term Effect and Safety of Antidiuretic Hormone in the Patients with Nocturia by Kang, Dong Il et al.
INJ
This is an Open Access article distributed under the terms of the Creative Commons Attri-
bution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which 
permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Copyright © 2010 Korean Continence Society  www.einj.or.kr
Int Neurourol J 2010;14:227-231
International Neurourology Journal 
Short Term Effect and Safety of Antidiuretic Hormone in the 
Patients with Nocturia
Dong Il Kang
1, Hak Min Kim
1, Seung Yeob Oh
1, Jang Ho Yoon
1, Hyun Min Kim
2, Kweon Sik Min
1,3
1Department of Urology, Pusan Paik Hospital, Inje University College of Medicine, Busan;
2Department of Urology, Sahmyoook Medical Center, Seoul;
3Paik Institute of Clinical Research, Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea
Purpose: To investigate the short-term safety of antidiuretic hormone in elderly patients with nocturnal polyuria, focus on hy-
ponatremia and others electrolytes disturbances and to assess short-term effects on nocturnal urine output and number of noc-
turnal voids.
Methods: Between June 2005 and August 2006, a total of 34 patients with nocturnal polyuria were orally administered 0.2 mg 
desmopressin tablet at bedtime for two weeks. Serum sodium, others electrolytes, urine sodium and urine osmolarity were as-
sessed in the third days, one week and two weeks after treatment with desmopressin and compared adult group (<65 years of 
age) with elderly group (≥65 years of age). We assessed the effect of desmopressin using a frequency-volume charts and anal-
ysed.
Results: In total 34 patients (20 adult, 14 elderly) were analyzed. Desmopressin treatment did not significantly change serum 
and urine electrolytes include soduim concentration in elderly patients comparied with adult patients. Serum sodium concen-
tration below normal range was recorded in 2 patients in elderly group, but no serious adverse events occurred and recovered 
without sequelae. The mean number of nocturnal voids decresed (54% reduction) and nocturnal urine output decreased (57% 
reduction) after using desmopressin.
Conclusions: Desmopressin was well tolerated and effective in elderly patients with nocturnal polyuria without clinically signif-
icant hyponatremia. 
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INTRODUCTION
Nocturia is a common cause of sleep disturbance in elderly 
people, and several studies have reported that its frequency in-
creases as the patient ages [1-3]. It had generally been accepted 
that bladder and prostate diseases induce adult nocturia, but re-
cently, the excessive production of urine has been found to be 
the major cause of nocturia. Various factors such as nocturnal 
polyuria, nocturnal detrusor overactivity, reduction of function-
al bladder capacity, and also abnormalities of the lower urinary 
tract have also been found to function as single or combined 
etiologic factors [4-6].
  Normally, the secretion of antidiuretic hormone increases 
during the night and nocturnal urine output is reduced to mini-
mize urine-induced awakening. A reduction of antidiuretic hor-
mone secretion seems the major factor in the nocturia caused by 
nocturnal polyuria [7,8]. With aging, the secretion of antidiuret-
ic hormone during the night declines to maintain a similar level 
during the day and night, and this lack of difference becomes the 
major cause of adult nocturia [8].
  Changes in the level of antidiuretic hormone are the theoreti-
cal basis for the usage of desmopressin, which is an analogue of 
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arginine vasopressin, an antidiuretic hormone secreted from 
the posterior lobe of the hypophysis. An incresing number of 
reports indicate that administration of desmopressin to patients 
with nocturia seems to improve their symptoms [9]. However, 
several studies have also reported that headache, vomiting, diz-
ziness, heart failure, and hyponatremia often appear [10]. Hy-
ponatremia in particular not only seems to occur more often in 
the elderly, but can also be fatal in this population; therefore, 
special caution is needed. Awareness of nocturia caused by noc-
turnal polyuria has been increasing in Korea, and therefore, the 
clinical use of desmopressin in adult nocturia patients is increas-
ing. Only a few studies, however, have reported on the effects 
and safety of its administration. Therefore, although its effects 
are recognized, we are still fearful of the possible side effects.
  Accordingly, we aimed to study the effects and also the inci-
dence of adverse effects with desmopressin treatment.
MATERIALS AND METHODS
From June 2005 to August 2006, voiding diary information was 
collected from outpatients who visited the urology department 
in our hospital with complaints of nocturia. Among these pa-
tients, 34 adults, aged 29-71 years, experiencing nighttime uri-
nation of more than 2 times per night and also more than 33% 
of urine volume/day, were enrolled.
  At the first visit, information on the patient’s medical history 
and voiding diary was collected, and physical examinations with 
liver and renal function tests were performed. Serum electro-
lytes, urine electrolytes, and urine osmolality were also measured 
to exclude patients showing abnormal antidiuretic hormone 
levels as the result of chlorpropamide, clofibrate, or carbamaze-
pine medication or those with heart failure, renal failure, or uri-
nary tract infection.
  Drug safety was analyzed by comparing the results of serum 
electrolytes, renal function tests, urine electrolytes, and changes 
in urine osmolality on the 3rd, 7th, and 14th days after the start 
of medication. Other health problems compared with the pre-
vious point of administration were also investigated at the out-
patient clinic by use of simple questionnaires and phone calls, 
and the treatment effect on nocturia was evaluated by compar-
ing the data from each voiding diary on the number of urina-
tions and the amount of urine recorded during the 3 days be-
fore the start of treatment and the 2 weeks of administration.
  Antidiuretic hormone (0.2 mg) was prescribed to the subjects 
to be administrated orally once a day, before bedtime. We gave 
directions to the subjects about limiting excessive water drink-
ing after dinner and also their alcohol and caffeine intake dur-
ing the medication period. We also provided information that 
side effects including headache, vomiting, dizziness, edema, hy-
ponatremia, and seizures could occur during the study. The 
subjects were divided into the elderly group (older than 65 years 
old) and the younger adult group to compare changes in serum 
and urine electrolytes, before and after treatment, to investigate 
the occurrence of adverse events, and finally to define the effi-
cacy of the treatment.
  For the statistical analysis, we used SPSS (SPSS Inc., Chicago, 
IL, USA) and the paired t-test to verify the significance of the 
change in electrolyte levels, before and after the antidiuretic hor-
mone medication, and P-values less than 0.05 were considered 
to indicate statistical significance. Serum sodium levels between 
135 and 145 mmol/L were considered normal, and levels under 
135 mmol/L were defined as hyponatremia.
RESULTS
A total of 34 patients were included in this study, with 14 patients 
(mean age, 69±3.6 years) included in the elderly group, and 20 
patients (mean age, 54.3±8.09 years) in the younger adult group. 
Comparing the results between the groups, average daily total 
urine volumes were 1,753±453 mL and 1,582±416 mL, amounts 
of nighttime urine volume were 573.1±72.7 mL and 590±83.1 
mL, night urination frequencies were 5.0±1.9 and 5.0±2.0 
times, and average sleep time was 7.3±1.12 and 7.6±1.16 hours, 
respectively (Table 1). 
  The average serum sodium level of the total subjects changed 
from 141.0 mmol/L (baseline) to 139.6 mmol/L (3rd day), 140.3 
mmol/L (7th day), and 139.8 mmol/L (14th day), which was 
Table 1.  Baseline patient characteristics
Characteristic ≥65 yr  <65 yr
No. of patients 14 20
Age (yr) 69.0±3.6 54.3±8.09
Body mass index (kg/m
2) 22.1±2.6 23.4±4.0
Nocturnal volume (mL) 573.1±72.7 590±83.1
Nocturnal volume weight (mL/kg) 9.55±1.7 9.27±1.62
24 hr urine volume (mL) 1,753±453 1,582±416
No. of nocturnal void 5.0±1.9 5.0±2.0
Duration of night 7.3±1.12 7.6±1.16
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not a statically significant reduction after the desmopressin med-
ication. Comparing levels measured on each day of both groups, 
the elderly group (≥65 years old) showed a more reduction on 
the 3rd day (141.5 mmol/L to 139.8 mmol/L to 140.8 mmol/L 
to 140 mmol/L at baseline and on days 3, 7, and 14, respective-
ly), and the younger adult group showed 140.7 mmol/L to 139.6 
mmol/L to 140.0 mmol/L to 139.7 mmol/L at baseline and on 
days 3, 7, and 14, respectively (Table 2, Fig. 1). However, these 
two groups did not show statistical significances.
  Of the total 34 subjects, only 2 patients in the elderly group 
(n=14) showed findings of hyponatremia, and their serum so-
dium levels returned to normal without any special treatments 
after stop of desmopressin. We also found no severe side effects 
such as clinically significant headache, nausea, abdominal pain, 
allergic reactions, or edema (Table 3). At the 3rd day, the urinary 
sodium level in the elderly group significantly decreased to 98% 
of the level before treatment, whereas the urine osmolality in-
creased to 125%, but without statistical significance compared 
to baseline. We also found no significant changes in blood or 
urine potassium, chloride, or creatinine levels.
  Two weeks after the initiation of treatment, effects of the med-
ication were seen in the decreased number of nocturia episode 
of 2.5±1.5 in the elderly group and 2.8±1.3 in the adult group. 
The amount of nocturia also decreased to 260±131 mL and 
309±116 mL in each group, respectively, which were statistical-
ly significant improvements (Table 4). 
Table 2.  Values of significant variables before and after dosing with desmopressin compared to baselilne. There are no statistical sig-
nificance in all compared to baseline
Base 3 days 7 days 14 days
<65 yr Serum
Na (mmol/L) 140.79±2.65 139.63±1.83 140.05±2.29 139.79±2.57
Urine
Na (mmol/L) 145.40±82.80 147.75±53.41 133.30±48.43 131.40±47.09
Osmolarity (mOsm/kg) 639.35±190.58 680.65±209.53 669.00±195.98 712.50±156.58
≥65 yr Serum
Na (mmol/L) 141.50±2.17 139.79±3.44 140.79±2.48 140.00±2.77
Urine
Na (mmol/L) 109.29±62.99 104.21±51.39 113.71±58.75 120.57±69.21
Osmolarity (mOsm/kg) 531.07±199.44 671.86±180.99 590.14±194.17 636.93±164.76
Values are presented as mean±SD.
Table 3.  Number of patients with hyponatremia based on age 
and basal serum sodium
Age
Basal serum 
sodium (n)
3rd days 7th days 14th days
<65 Normal (20) 0 0 0
Low (0) 0 0 0
≥65  Normal (14) 0 0 0
Low (0) 2 0 0
Table 4.  The changes from baseline in voiding variables for all 
patients and by age
Variable  All ≥65 yr <65 yr
No. of nocturnal voids -2.7±1.34 -2.5±1.5 -2.8±1.3
Nocturnal urine 
  volume (mL)
-288±122 -260±131 -309±116
Values are presented as mean±SD. P<0.05 compared to baseline.
Fig. 1. The serum sodium values at base-line, the third, seventh 
and fourteenth days of desmopressin treatment. There are no 
statistical significance in all compared to baseline.
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DISCUSSION 
Nocturia is a major cause of decline in the quality of life of elder-
ly people, and interest in this problem has been growing as a re-
sult of the increased proportion of the elderly population owing 
to their increasing life expectancy. Regardless of the cause, noc-
turia is a very common lower urinary tract symptom, and more 
than 72% of older people say that they have experienced noctu-
ria more than at least once during their sleep, and 24% have ex-
perienced nocturia of three or more times per night [11,12].
  Because lower urinary tract abnormalities of the bladder or 
prostate are considered to be major causes of lower urinary tract 
symptoms, medications such as alpha blockers, 5-alpha reduc-
tase inhibitors, and anticholinergics or surgical treatments are 
usually considered as the first line of treatment. However, such 
treatments often result in no significant improvements.
  Nocturia in elderly people can be classified into nocturnal 
polyuria, detrusor overactivity, mixed-type, and polyuria accord-
ing to the cause, and nocturnal polyuria and detrusor overac-
tivity account for more than 75% of cases [13]. Nocturnal poly-
uria is known to be related to changes in biological rhythms, 
over-intake of water, loss of body fluid, reduced concentrating 
ability of the proximal tubule induced by diuretics, change of in 
the glomerular filtration rate, insensitive diurnal variation of 
antidiuretic hormone, reduced secretion of renin-angiotensin-
aldosterone system, and also the secretion of atrial natriuretic 
peptide, caused by aging [14-16]. Detrusor overactivity could 
be induced by detrusor hyperreflexia caused by neurological 
diseases, urethral stricture, prostatic hyperplasia, and detrusor 
instability caused by bladder disorders; regardless of its cause, 
detrusor overactivity can induce nocturia [13]. Bladder outlet 
obstruction, detrusor overactivity, and the decrease in func-
tional bladder capacity caused by neurogenic bladder disorder 
can also cause nocturia [17,18].
  Desmopressin, an analogue of the Antidiuretic hormone, ar-
ginine vasopressin, functions at the collecting duct to stimulate 
the reabsorption of water and reduce the production of urine. 
Desmopressin is a selective drug for central type diabetes insip-
idus with proven reliability. It is also known to have effects on 
adult nocturia caused by nocturnal polyuria [19]. However, it 
can potentially cause fatal side effects such as hyponatremia, 
caused by water retention. It has been reported in several stud-
ies that 12 to 22% of patients who are taking antidiuretic hor-
mone analogues have experienced hyponatremia more than 
once. Another recent meta-analysis study of the risk of hypona-
tremia in patients using this drug reported that hyponatremia 
accompanying clinical symptoms such as headache, nausea, 
vomiting, fatigue, dizziness, ataxia, or weight gain had occurred 
in 31 of the total 632 patients (4.9%) [20-22]. The age of the pa-
tient was reported to be the most associated risk factor for hy-
ponatremia; others included a serum sodium level lower than 
base line, urine output during the daytime higher than weight, 
and also increased body weight [22]. In addition to hyponatre-
mia, desmopressin could also affect the excretion of electrolytes 
because urine osmolality increases after the administration of 
an antidiuretic hormone analogue, with increased urinary cal-
cium excretion or decreased urinary potassium excretion of 
nocturia [23].
  Antidiuretic hormone analogues have been used in the treat-
ment of pediatric enuresis without any reports of serious side 
effects, and many reports on the administration of these drugs 
to adult nocturia patients have been published with no reports 
of severe side effects such as altered mental state, seizures, or 
congestive heart disease caused by water retention resulting in 
hyponatremia. Other mild clinical symptoms such as edema, 
nausea, and headache occurred only temporally or were resolved 
by discontinuing the medication or by simple treatments such 
as drinking sufficient water.
  In this study, we also found that antidiuretic hormone ana-
logue treatment of adults with nocturia significantly reduced 
nocturia and also the amount of urine, and we found no signifi-
cant decrease in the serum sodium level. Of the total 34 subjects, 
only 2 patients in the elderly group showed symptoms of hypo-
natremia, but their levels returned to normal without any spe-
cial treatments. We also found no clinically significant side ef-
fects such as headache, nausea, abdominal pain, allergic reac-
tions, or edema.
  In this short-term study of treatment of adult nocturia with 
antidiuretic hormone analogues, we observed no clinically sig-
nificant adverse events caused by hyponatremia. It appears that 
this therapy could be safely used to treat adult nocturia patients. 
However, in elderly patients, sufficient guidelines about adequate 
water-drinking after dinner, limiting alcohol and caffeine intake, 
and routine body weight measurements should be provided, 
and follow-up studies to measure serum electrolytes should 
also be performed. Moreover, further studies about the long-
term efficacy and safety of antidiuretic hormone analogue ad-
ministration in adult nocturia patients should be continuously 
performed. www.einj.or.kr    231
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